Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.

Alzheimer's disease (AD) is the most common form of dementia in adults, which is characterized by senile plaquets and cholinergic deficit as the disease progresses. Improvement of cholinergic neurotransmission is the basis of some drugs currently used in the treatment of AD. It is achieved by acetylcholinesterase (AChE) inhibition, the enzyme responsible for acetylcholine hydrolysis. Molecular modeling techniques were of utmost importance to design a new pharmaceutical against Alzheimer's disease, with potential inhibitory activity over AChE, since the inhibition of human plasma butyrylcholinesterase (BChE) may cause side effects. Some of the drugs currently used in the treatment of AD are capable of increasing the cholinergic transmission through the AChE inhibition. In this work we proposed molecular hybrids of tacrine with donepezil (fusion of these structures), in order to suggest new proposals of AChE inhibitors for future treatment of AD. We have analyzed all the structures by docking, density functional studies and drug like properties.

[1]  F. J. Luque,et al.  New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. , 2000, Journal of medicinal chemistry.

[2]  A. Leo,et al.  Substituent constants for correlation analysis. , 1977, Journal of medicinal chemistry.

[3]  A. Shepherd.  Introduction to Medicinal Chemistry by D. Maclean, D. Evans and John Bowen Jones. Pp.276. Harper & Row Inc., New York, 1976. £6.95 , 1976 .

[4]  J L Sussman,et al.  X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. , 2002, Biochemistry.

[5]  Akash Khandelwal,et al.  A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands. , 2005, Journal of medicinal chemistry.

[6]  W. Reichman.  Current pharmacologic options for patients with Alzheimer's disease , 2003, Annals of general hospital psychiatry.

[7]  A. Leo,et al.  Substituent constants for correlation analysis in chemistry and biology , 1979 .

[8]  K. M. Uchida,et al.  Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  Tudor I. Oprea,et al.  Chemoinformatics in drug discovery , 2005 .

[10]  Jean-Pierre Toutant,et al.  aCHEdb: the database system for ESTHER, the alpha/beta fold family of proteins and the Cholinesterase gene server , 1998, Nucleic Acids Res..

[11]  E. Giacobini.  Cholinergic foundations of Alzheimer's disease therapy , 1998, Journal of Physiology-Paris.

[12]  Carlos H. Tomich P. Silva,et al.  Homology modeling and molecular interaction field studies of α-glucosidases as a guide to structure-based design of novel proposed anti-HIV inhibitors , 2005, J. Comput. Aided Mol. Des..

[13]  J. Sussman,et al.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Ariel,et al.  Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. , 2000, Acta crystallographica. Section D, Biological crystallography.

[15]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[16]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[17]  Hongqi Xu.  Nanotubes: the logical choice for electronics? , 2005, Nature materials.